1.Sivri B, Müderrisoğlu H, Kansu E, Atahan L, Özerkan K, Batman F, Arıoğul S, Barışta İ, Doyran B, Sert Z, Güllü İ. Yüksek Doz Radyasyonun İnsan Vücuduna Etkileri (İki Vaka Nedeniyle). İç Hastalıkları Dergisi (The Turkish Journal of Internal Medicine),1987;1(4):147-153. 2.Uzun Ö, Akan Ö, Akalın E, Barışta İ, Kansu E, Tekuzman G. Antifungal Therapy in Patients with Fever and Granulocytopenia. Kanser, The Turkish Journal of Cancer 1989;19(3):108-113. 3.Akan Ö, Hasçelik G, Korten V, Barışta İ, Baykal M, Akalın E.B Grubu Streptokokkal Endokardit. Mikrobiyoloji Bülteni, 1990; 24:357-360. 4.Özyılkan Ö, Ünlü E, Tekuzman G, Ruacan Ş, Baltalı E, Güler N,Güllü İH, Barışta İ, Özışık Y, Fırat D. Superior Vena Cava Syndrome: A 15 Year Period Experience. Kanser, The Turkish Journal of Cancer 1991; 21(3):109-115. 5.Güllü İ, Tekuzman G, Güler N, Barışta İ, Alakavuklar M, Kars A, Özışık Y, Baltalı E, Özdemir O, Kansu E, Fırat D. Baş-Boyun Tümörlerinde Cisplatin, Bleomycin, 5-Fluorouracil, Methotrexate Kombine Kemoterapisinin Değerlendirilmesi. Türk Hematoloji Onkoloji Dergisi (THOD) 1991;1(1):15-23. 6.Barışta İ, Tekuzman G, Baltalı E, Güllü İ, Fırat D, Kansu E, Kars A, Özışık Y, Güler N, Özdemir O. İleri Evre Hodgkin Lenfomalı Hastalarda COPP/ABVD ve ABVD Kemoterapileri. Türk Hematoloji Onkoloji Dergisi (THOD) 1991;1(1):40-47. 7.Demirkazık A, Güllü İH, Baltalı E, Kars A, Tekuzman G, Koç Y, Güler N, Barışta İ, Fırat D. Evre II-III Meme Kanserlerinde Adjuvant Kemoterapi Olarak L-Phenyl- alanine Mustard (L-PAM) Kullanımı. Türk Hematoloji Onkoloji Dergisi(THOD) 1991;1(3):133-136. 8.Özyılkan Ö, Tekuzman G, Ünlü E, Güllü İH, Güler N, Barışta İ, Baltalı E, Özışık Y, Ruacan Ş, Fırat D. Küçük Hücreli Akciğer Kanserinde Performans Statüsü ve Yaşın Prognoza Etkisi. Türk Hematoloji Onkoloji Dergisi (THOD) 1991;1(3):179- 182. 9.Barışta İ, Kabakçı G, Dündar S, Turgan Ç, Caymaz O. Nefrotik Sendromlu Hastalarda Protein-C, Protein-S, Anti-thrombin III Düzeyleri. Türkiye Klinikleri, Türk Tıp Araştırma Dergisi 1992;10(1):43-47. 10.Barışta İ, Güllü İH. Non-Hodgkin Lenfomalarda Kromozomal Değişiklikler. Türk Hematoloji Onkoloji Dergisi (THOD) 1992;2(1):33-35. 11.Barışta İ, Baltalı E, Güllü İH, Akpolat T, Tekuzman G, Karaağaoğlu E, Sungur A, Kars A, Güler N, Özyılkan Ö, Fırat D. Metastatik Meme Karsinomlarında Metastazların Dokulara Dağılımını Etkileyen Faktörler. Türk Hematoloji Onkoloji Dergisi (THOD) 1992;2(2):80-85. 12.Güllü İ, Tekuzman G, Barışta İ, Baltalı E, Kars A, Güler N, Özyılkan Ö, Atahan İL, Hoşal N, Fırat D. Adjuvant Chemotherapy for Locally Advanced Head and Neck Cancers: Preliminary Report. Türk Hematoloji Onkoloji Dergisi (THOD) 1992; 2(3):137-141. 13.Barışta İ, Tekuzman G, Güllü İH, Özyılkan Ö, Özışık Y, Güler N, Kars A, Baltalı E, Fırat D. Primer Kolon Lenfomaları. Kolon ve Rektum Hastalıkları Dergisi 1992;2(4):173-176. 14.Barışta İ, Kars A. Low Grade Lenfomaların Klinik Özellikleri ve Tedavisi. İlaç ve Tedavi Dergisi (The Turkish Journal of Drugs and Therapeutics) 1992;5(9):529- 534. 15.Güllü İH, Yalçın Ş, Tekuzman G, Kars A, Güler N, Baltalı E,Barışta İ, Fırat D, Bekdik C, Koray Z. Tumor Markers in Effusions: A Comparative Study of Tumor Marker Levels in Sera and Effusions. In:Travis CC, editor. Use of Biomarkers in Assessing Health and Environmental Impacts of Chemical Pollutants, New York: Plenum Press,1993:265-271. 16.Özyılkan Ö, Özyılkan E, Kars A, Karaağaoğlu E, Tatar G, Barışta İ, Tekuzman G, Baltalı E, Fırat D. Evaluation of Prognostic Factors with Respect to Survival of Colorectal Cancer Patients. Kanser, The Turkish Journal of Cancer 1993; 23(2): 59-67. 17.Güllü İH, Tekuzman G, Baltalı E, Kars A, Barışta İ, Güler N, Özyılkan Ö, Özışık Y, Fırat D. Cisplatin and Five-day Continous Infusion of 5-Fluorouracil in Patients with Recurrent and Disseminated Carcinoma of the Head and Neck. Cancer. Kanser, The Turkish Journal of Cancer 1993; 23(2):68-74. 18.Kitapçı MT, Taştekin G, Turgut M, Caner B, Kars A, Barışta İ, Bekdik C. Preoperative Localization of Parathyroid Carcinoma Using Tc-99m MIBI. Clinical Nuclear Medicine 1993;18(3):217-219. 19.Güllü İH, Barışta İ, Güler N, Tekuzman G, Sungur A. B-Cell Lymphoma with Uterine Corpus Involvement. A Case Report. Journal of Ankara Medical School 1993; 15(2):617-621. 20.Barışta İ, Tekuzman G, Güllü İH, Özyılkan Ö, Özışık Y, Güler N, Kars A, Baltalı E, Kansu E, Fırat D. Primary non-Hodgkin’s Lymphoma of the Stomach: Diagnostic Findings and Treatment Results. Kanser, The Turkish Journal of Cancer 1993; 23(3):118-125. 21.Özyılkan Ö, Tekuzman G, Kars A, Barışta İ, Baltalı E, Ruacan Ş, Özışık Y, Kansu E, Fırat D. Single-agent and Combination Chemotherapy in Small Cell Lung Cancer. Kanser, The Turkish Journal of Cancer 1993; 23(3):126-133. 22.Güllü İH, Barışta İ, Tekuzman G. Cancer and Thrombosis. Kanser, The Turkish Journal of Cancer 1994;24(1):5-13. 23.Barışta İ, Güllü İ, Akpek G, Eldem B, Demirkazık F, Ayhan A, Baltalı E, Tekuzman G, Fırat D. Non-Hodgkin Lenfomalarda Oküler ve Orbital Tutulum. Türk Hematoloji Onkoloji Dergisi (THOD) 1994;4(1):54-59. 24.Özışık Y, Kars A, Barışta İ, Tekuzman G, Kansu E, Fırat D. The Role of Bleomycin, Cyclophosphamide, Mitoxantrone, Vincristine, and Prednisone (BCNOP) in non-Hodgkin’s Lymphoma. Kanser, The Turkish Journal of Cancer 1994;24(1):20-27. 25.Altınbaş M, Barışta İ, Tekuzman G, Baltalı E, Alkış N, Güllü İ, Güler N, Gököz A, Kölemen F. Mycosis Fungoidesli Hastalarda Tedavi Sonuçları.Türkiye Klinikleri Dermatoloji Dergisi 1994;4(1):1-4. 26.Baltalı E, Akpek G, Tekuzman G, Barışta İ, Kars A, Fırat D. Treatment of Metastatic Adenocarcinoma of Prostate with Orchiectomy and Flutamide. Kanser, The Turkish Journal of Cancer 1994;24(3):138-146. 27.Güllü İ, Tekuzman G, Baltalı E, Barışta İ, Kars A, Güler N, Akpek G, Fırat D. 5-Fluorouracil, Adriamycin and Mitomycin-CCombination Chemotherapy for Advanced Gastric Carcinoma. Kanser, The Turkish Journal of Cancer 1994;24(3):147-156. 28.Barışta İ, Tekuzman G, Fırat D, Baltalı E, Kansu E, Kars A, Özışık Y, Ruacan Ş, Uzunalimoğlu B, Karaağaoğlu E. Non-Hodgkin’s Lymphomas in Turkey: Eighteen Years’ Experience at the Hacettepe University. The Japanese Journal of Cancer Research 1994;85(12):1200-1207. 29.Yalçın Ş, Savaş MC, Güllü İ, Tekuzman G, Barışta İ, Çelik İ, Altınbaş M, Güler N, Kars A, Baltalı E, Fırat D. Efficiacy of Oral Ketorolac Tromethamine Compared with Dipyron in Patients with Cancer Pain. Türk Hematoloji Onkoloji Dergisi (THOD) 1994;4(3):146-150. 30.Barışta İ, Güllü İH, Baltalı E, Gököz A, Tekuzman G. Mikozis Fungoides Tedavisinde İnterferon ve Methotrexate. Dermatopatoloji Dergisi 1994;3(3- 4):120-123. 31.Haznedaroğlu Ş, Güllü İH, Haznedaroğlu İ, Baltalı E, Barışta İ, Tekuzman G, Güler N, Altınbaş M, Kars A, Fırat D. Gastrointestinal Sistem Kanserlerinde CEA ve CA 19-9 Tümör Belirleyicilerinin Klinik ve Tedavideki Önemi. Acta Oncologica Turcica 1994;27(3-4): 53-59. 32.Yalçın Ş, Tekuzman G, Barışta İ, Güllü İ, Abbasoğlu O, Sayek İ, Fırat D. Non- Hodgkin Lenfomalı Bir Olguda Gelişen Sekonder Kolon Kanseri. Acta Oncologica Turcica 1994;27(3-4):95-96. 33.Demiroğlu H, Özcebe Oİ, Barışta İ, Dündar S. Multiple Myelomda Çeşitli Kemoterapi Protokollerinin Karşılaştırılması ve Prognostik Faktörlerin Belirlenmesi. Türk Hematoloji Onkoloji Dergisi (THOD) 1995;5(1):20-26. 34.Barışta İ, Tekuzman G, Güllü İ, Baltalı E, Kars A, Özışık Y, Güler N, Çelik İ, Atahan İL, Fırat D. Non-Hodgkin’s Lymphomas of the Tonsil: A Retrospective Analysis of Twenty-eight Patients with Primary Tonsillary Lymphoma. Tumori 1995;81(4):234-237. 35.Barışta İ, Çelik İ, Güllü İ, Hayran M, Akova M. Integrating the Time Factor into the Definition of Metastasis of Unknown Origin. Journal of the National Cancer Institute 1996;88(1): 51. 36.Çelik İ, Baltalı E, Barışta İ, Tekuzman G, Kansu E, Atahan L, Güngen Y, Fırat D. Solitary Phalanx Plasmacytoma Relapse with Disseminated Extramedullary Plasmacytomas and Myeloma After Short Duration of Remission. Anticancer Research 1996;16(2): 959-962. 37.Demiroğlu H, Barışta İ, Gürsoy M, Oymak O, Dündar S. The Effect of Desmopressin (DDAVP) on Platelet Aggregation Defect in Systemic Amyloidosis: A preliminary report. European Journal of Haematology 1996; 56(5): 283-286. 38.Demiroğlu H, Barışta İ, Dündar S. Erythrocyte Aggregability in Patients with Coronary Heart Disease. Clinical Hemorheology 1996; 16(3): 313-317. 39.Güllü İ, Yalçın Ş, Tekuzman G, Barışta İ, Alkış N, Çelik İ, Zengin N, Güler N, Kars A, Baltalı E, Kansu E, Fırat D. High-dose Ifosfamide by Infusion withMesna in Advanced Refractory Sarcomas. Cancer Investigation 1996;14(3): 239-242. 40.Güllü İH, Çelik İ, Tekuzman G, Altınbaş M, Güler N, Barışta İ, Alkış N, Yalçın Ş, Kars A, Baltalı E, Kansu E, Fırat D. Procarbazine, CCNU, Vincristine Combination in the Treatment of Brain Tumors. Tumori 1996;82(3):228-231. 41.Barışta İ. AIDS: Kanser. İnfeksiyon Bülteni 1996;1(3):100-104. 42.Yalçın Ş, Barışta İ, Tekuzman G, Güllü İ, Fırat D. Dramatic Response to Ifosfamide, Mesna and Doxorubicin Chemotherapy Regimen in an Adult with Clear Cell Sarcoma of the Kidney. The Journal of Urology 1996; 155: 2024. 43.Çelik İ, Barışta İ, Fırat D. Cancer Therapy during Ramadan. Journal of the National Cancer Institute 1996;88(12):838. 44.Kiraz S, Baltalı E, Güler N, Barışta İ, Benekli M, Çelik İ, Güllü İH, Kars A, Tekuzman G, Fırat D. Ifosfamide, Mesna and Epirubicin as Second-line Chemotherapy in Advanced Breast Cancer. Journal of Chemotherapy 1996;18(4): 310-314. 45.Çelik İ, Barışta İ, Tekuzman G, Kansu E, Kiraz S, Çalgüneri M. Behçet Disease: Advantageous Against Developmentof Neoplasia?Annals of Rheumatic Diseases 1996; 55(9):648. 46.Çelik İ, Başçıl N, Güllü İ, Barışta İ, Çamurdanoğlu M. Difficult Diagnosis in a Patientwith Multiple Osteoblastic Thoracic Vertebral Lesions. Annals of Saudi Medicine 1996; 16(5):590. 47.Çelik İ, Barışta İ, Akhan S, Erdem Y, Tekuzman G. Metastatic Germ Cell Tumor Presenting with Renovascular Hypertension. Nephron 1996; 74:486-487. 48.Yalçın Ş, Güler N, Kansu E, Ertenli İ, Güllü İ, Barışta İ, Çelik İ, Kars A, Tekuzman G, Baltalı E, Fırat D. Granulocyte - Colony Stimulating Factor (G-CSF) Administration for Chemotherapy-induced Neutropenia. Hematology 1996; 1(2):155-161. 49.Demiroğlu H, Barışta İ, Dündar S. Assessing the Risk of Deep Vein Thrombosis in Behçet’s Disease. Thrombosis Research 1996; 84(4):297-298. 50.Barışta İ, Baltalı E, Güllü İH, Güler N, Çelik İ, Saraçbaşı O, Tekuzman G, Kars A, Özışık Y, Ruacan Ş, Atahan İL, Fırat D. Factors Influencing the Distribution of Metastases and Survival in Metastatic Breast Carcinoma. American Journal of Clinical Oncology 1996;19(6):569-573. 51.Barışta İ. Comments on Current and Future Trends in the Multidisciplinary Approach for High-risk Breast Cancer. The Experience of the Milan Cancer Institute. European Journal of Cancer 1997; 33:(1):164-165. 52.Topeli A, Barışta İ, Çelik İ, Kansu E. Timing of Therapy in Vasculitis-associated Multiple Myeloma: Comment on the Article by Hasegawa et al. Arthritis and Rheumatism 1997; 40(2): 395-396. 53.Demiroğlu H, Barışta İ, Dündar S. The Effects of Age and Menopause on Erythrocyte Aggregation. Thrombosis and Haemostasis 1997;77(2):404. 54.Güler N, Kansu E, Türker A, Barışta İ, Kanra T. Severe Autoimmune Hemolytic Anemia in Hairy Cell Leukemia. European Journal of Haematology 1997; 58(3):205-206. 55.Çelik İ, Başçıl N, Yalçın Ş, Güllü İH, Kars A, Barışta İ, Tekuzman G. Ifosfamide- based Chemotherapyfor Recurrent or Metastatic Hemangiopericytoma. Acta Oncologica, 1997; 36(3):348. 56.Kiraz S, Baltalı E, Güler N, Barışta İ, Benekli M, Çelik İ, Güllü İH, Kars A, Tekuzman G, Fırat D. Ifosfamide and Etoposide in Previously Treated Patients with Advanced Breast Cancer. Tumori 1997; 83(2): 604-607. 57.Demiroğlu H, Barışta İ, Dündar S. Risk Factor Assessment and Prognosis of Eye Involvement in Behçet’s Disease in Turkey. Ophthalmology 1997; 104(4):701-705. 58.Kadayıfçı A, Benekli M, Savaş MC, Arslan S, Uzunalimoğlu B, Barışta İ, Güllü Hİ, Tekuzman G. Multiple Lymphomatous Polyposis. Journal of Surgical Oncology 1997; 64(4):336-340. 59.Altınbaş M, Barışta İ, Alkış N. Tiroid Kanserlerinin Dağılımı- Ankara Onkoloji Hastanesi Sonuçları. Türkiye Klinikleri Tıp Bilimleri Dergisi 1997; 17(2):120-124. 60.Zengin N, Kars A, Kansu E, Özdemir O, Barışta İ, Güllü İ, Güler N, Özışık Y, Dündar S, Fırat D. Comparison of Rai and Binet Classifications in Chronic Lymphocytic Leukemia. Hematology 1997; 2:125-129. 61.Barışta İ, Yazıcı KM, Tekuzman G. Psychiatric Morbidity in Terminally Ill Cancer Patients. A Prospective Study. Cancer 1997; 79(9):1848-1849. 62.Altınbaş M, Güler N, Tekuzman G, Baltalı E, Kars A, Özışık Y, Güllü İ, Barışta İ, Fırat D. Yumuşak Doku Sarkomlarının Dağılımı: Hacettepe Üniversitesi Tıp Fakültesi Sonuçları. Türk Onkoloji Dergisi 1997; 12(2):32-36. 63.Barışta İ, Çelik İ, Güllü İ, Yalçın Ş. Intrathecal Chemotherapy and Bone Marrow. Leukemia 1997; 11(8):1392-1393. 64.Kars A, Çelik İ, Kansu E, Tekuzman G, Özışık Y, Güler N, Barışta İ, Güllü İ, Yalçın Ş, Altundağ K, Zengin N, Türker A, Hayran M, Baltalı E, Fırat D. Maintenance Therapy with Alpha-Interferon Following First-Line VAD in Multiple Myeloma. European Journal of Haematology 1997; 59(2):100-104. 65.Barışta İ. An Association Between Renal Cell Carcinoma and Lymphoid Malignancies. A Case Series of Eight Patients. Cancer 1997;80(5):1004-1005. 66.Çelik İ, Başçıl N, Barışta İ, Güllü İ, Tekuzman G, Fırat D. Primary Central Nervous System Lymphoma Presenting with Multiple Myeloma-Like Clinical Picture. Journal of Neurology, Neurosurgery and Psychiatry 1997; 63(3):409-410. 67.Yalçın Ş, Demiroğlu H, Güllü İ, Barışta İ. Lupus Nephritis in a Patient with Idiopathic Thrombocytopenic Purpura Diagnosed 11 Years Earlier. Clinical Nephrology 1997; 47(3):201-202. 68.Dinçol D, Mandel Molinas N, Barışta İ, Aktan G, Onat H, Sardaş OS,Berk Ö, Çehreli C, Fırat D. Combination Chemotherapy Involving Weekly Epirubicin in the Treatment of Intermediate and High Grade non-Hodgkin Lymphomas. Kanser, The Turkish Journal of Cancer 1997; 27(3):91-97. 69.Özgür F, Akyürek M, Kayıkçıoğlu A, Barışta İ, Gököz A. Metastatic Malignant Blue Nevus: A case report. Annals of Plastic Surgery 1997; 39(4):411-415. 70.Barışta İ, Tekuzman G, Fırat D, Baltalı E, Kansu E, Kars A, Özışık Y, Ruacan Ş, Uzunalimoğlu B, Karaağaoğlu E. Non-Hodgkin's Lymphomas in Elderly. Kanser, The Turkish Journal of Cancer1997; 27(4):161-170. 71.Zengin N, Çelik İ, Kars A, Barışta İ, Güler N, Özışık Y, Güllü İH, Türker A, Yalçın Ş, Altundağ A, Kansu E, Tekuzman G, Baltalı E, Fırat D. Prognostic Significance of Age in Chronic Lymphocytic Leukemia. Kanser, The Turkish Journal of Cancer1997; 27(4):171-175. 72.Çelik İ, Kars A, Apraş Ş, Kansu E, Tekuzman G, Özışık Y, Güler N, Barışta İ, Güllü İH, Yalçın Ş, Altundağ K, Zengin N, Türker A, Baltalı E, Fırat D. Age as a Prognostic Parameter in Multiple Myeloma. Kanser, The Turkish Journal of Cancer1997; 27(4):176-182. 73.Öztürk MA, Benekli M, Güler N, Altundağ MK, Barışta İ, Ayhan A. Gastric Adenocarcinoma Metastasis to the Parotid Gland. Journal of Clinical Gastroenterology, 1997; 25:698-699. 74.Benekli M, Akpek G, Güllü İH, Ruacan Ş, Barışta İ, Ayhan A, Tekuzman G, Fırat D. Small Intestinal Perforation in Hodgkin’s Disease. Journal of Clinical Gastroenterology 1997; 25:699-701. 75.Çelik İ, Apraş Ş, Kars A, Barışta İ, Güllü İ, Güler N, Kansu E.Persistent Hypercalcemia Leading to Acute Pancreatitis in a Patient with Relapsed Myeloma and Renal Failure. Nephron 1998; 79:109-110. 76.Çelik İ, Kars A, Güler N, Barışta İ, Tekuzman G, Özyılkan Ö, Hayran M, Fırat D. Phase II Trial of MINE as a Front-line Therapeutic Modality in Intermediate- and High-grade non-Hodgkin’s Lymphomas. European Journal of Cancer 1998; 34(5):759-760. 77.Altundağ MK, Barışta İ. False-positive Urine Melanin Pigment Reaction Caused by Rifampin. The Annals of Pharmacotherapy 1998; 32(5):610. 78.Yalçın Ş, Güllü İH, Barışta İ, Tekuzman G, Özışık Y, Çelik İ, Kars A. Treatment of Advanced Sarcomas with Ifosfamide and Etoposide Combination Chemotherapy. Cancer Investigation 1998; 16(5):297-302. 79.Koç Y, Akpek G, Kansu E, Kars A, Tekuzman G, Baltalı E, Güler N, Barışta İ, Güllü İ, Özışık Y, Fırat D.Bolus and Continuous Infusion Mitoxantrone in Newly Diagnosed Adult Acute Lymphoblastic Leukemia: Results of Two Consecutive Phase II Clinical Studies. Cancer Investigation 1998; 16(6):355-365. 80.Yalçın Ş, Kars A, Özışık Y, Tekuzman G, Özyılkan Ö, Çelik İ, Barışta İ, Güllü İ, Güler N, Baltalı E, Fırat D. VB-CHEP Chemotherapy Regimen for Aggressive Non-Hodgkin’s Lymphomas. European Journal of Haematology 1998; 61(4): 261-265. 81.Demiroğlu H, Gürlek A, Barışta İ. Enhanced Erythrocyte Aggregation in Type 2 Diabetes with Late Complications. Experimental and Clinical Endocrinology and Diabetes 1999; 107:35-39. 82.Yalçın Ş, Tekuzman G, Baltalı E, Özışık Y, Barışta İ. Serotonin Receptor Antagonists in Prophylaxis of Acute and Delayed Emesis Induced by Moderately Emetogenic, Single Day Chemotherapy: A Randomized Study. American Journal of Clinical Oncology 1999; 22(1): 94-96. 83.Barışta İ. Biphosphonates and the Flare Phenomenon. Journal of Clinical Oncology 1999; 17(4):1328-1329. 84.Barışta İ, Benekli M, Tekuzman G. Amyloidosis in Hodgkin’s and Castleman’s Diseases. Annals of Oncology 1999; 10(8):998-999. 85.Yalçın Ş, Tekuzman G, Güllü İ, Kav T, Baltalı E, Kars A, Özışık Y, Güler N, Barışta İ, Çelik İ, Türker A, Altundağ K, Zengin N. Solid Tümörlerde Kemik İliği Metastazlarının Klinikopatolojik İncelenmesi: 21 Vakanın Analizi. Türk Hematoloji Onkoloji Dergisi (THOD) 1999; 9(3):159-161. 86.Barışta İ, Tekuzman G, Yalçın Ş, Güllü İ, Güler N, Özışık Y, Kars A, Çelik İ, Türker A, Altundağ K, Zengin N, Üner A, Baltalı E, Fırat D. Treatment of Advanced Soft Tissue Sarcomas with Ifosfamide and Doxorubicin Combination Chemotherapy. Journal of Surgical Oncology 2000; 73(1):12-16. 87.Demiroğlu H, Özcebe Oİ, Barışta İ, Dündar S, EldemB. Interferon alfa-2b, Colchicine, and Benzathine Penicillin versus Colchicine and Benzathine Penicillin in Behçet’s Disease: A Randomised Trial. Lancet 2000; 355(9204): 605-609. (Etik nedenlerle 14 Ekim 2000 tarihinde yayından çekilmiştir) 88.Barışta İ, Baltalı E, Tekuzman G, Kars A, Ruacan Ş, Özışık Y, Güler N, Güllü İH,Atahan İL, Fırat D. Primary Breast Lymphomas - A Retrospective Analysis of Twelve Cases. Acta Oncologica 2000; 39(2):135-139. 89.Barışta İ. Intrathecal Cytarabine and Bone Marrow Suppression. Journal of Clinical Oncology 2000; 18:2003-2004. 90.Aydın ZD, Barışta İ, Canpınar H, Sungur H, Tekuzman G.Gastric Lymphomas in Turkey. Analysis of Prognostic Factors with Special Emphasis on Flow Cytometric DNA Content. Cancer 2000;89(1):12-20. 91.Köklü S, Barışta İ, Altundağ MK, Aksu S, Fırat P. An Unusual Case of Metastatic Rectal Carcinoma Presenting as Thyroid Nodule. American Journal of Gastroenterology 2000; 95(12):3689. 92.Barışta İ, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. The Lancet Oncology 2001;2(3):141-148. (Orijinal makaledeki Tablo 1 için The Lancet Oncology 2002; 3(7):396’da Erratum yayınlanmıştır) 93.Göker H, Tekuzman G, Barışta İ, Güllü İ, Fırat D. İmmünoproliferatif İnce Barsak Hastalığı (IPSID):18 Yıllık Hacettepe Deneyimi. Türk Hematoloji Onkoloji Dergisi (THOD) 2001; 11(2):57-61. 94.Barışta İ, Cabanillas F, Romaguera JE, Khouri IF, Yang Y, Smith TL, Strom SS, Medeiros JL, Hagemeister FB. Is There an Increased Rate of Additional Malignancies in Patients with Mantle Cell Lymphoma? Annals of Oncology 2002; 13(2):318-322. 95.Wilder RB, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, Hagemeister FB, Barışta İ, Cabanillas F, Cox JD. European Organization for Research and Treatment of Cancer and Groupe d’Etude des Lymphomes de l’Adulte Very Favorable and Favorable, Lymphocyte-Predominant Hodgkin Disease. Cancer 2002; 94(6):1731-1738. 96.Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barışta İ,Hess MA, Cabanillas F, Cox JD. An Elevated Beta-2 Microglobulin Level Is An Adverse Prognostic Factor For Overall Survival In Patients With Early-Stage Hodgkin Disease. Cancer 2002; 95(12):2534-2538. 97.Öztürk MA, Barışta İ, Altundağ MK, Türker A, Yalçın Ş, Çelik İ, Güllü İH, Güler N, Özışık Y, Kars A, Kansu E, Baltalı E, Tekuzman G. Modified ESHAP as Salvage Chemotherapy for Recurrent or Refractory non-Hodgkin’s Lymphoma: Results of a Single-Center Study of 32 Patients. Chemotherapy 2002; 48(5):252- 258. 98.Oyan B, Güler N, Kars A, Türker A, Altundağ K, Özışık Y, Baltalı E, Çelik İ, Barışta İ, Güllü İ, Yalçın Ş, Hamaloğlu E,Öner Z, Tekuzman G. The Prognostic Predictors for Disease Free Survival and Overall Survival in Stage I-III Breast Cancer Patients Treated with Adjuvant Cyclophosphamide-Adriamycin-5 -Fluorouracil (CAF) Chemotherapy. Kanser, The Turkish Journal of Cancer 2002; 32(2):92-104. 99.Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barışta İ, Cabanillas F, Cox JD. Analysis of In-Field Control and Late Toxicity For Adults with Early-Stage Hodgkin’s Disease Treated with Chemotherapy Followed by Radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2003; 54(1):36-43. 100.Kılıçkap S, Abalı H, Barışta İ, Tekuzman G. Hacettepe Üniversitesi Onkoloji Enstitüsünde İzlenen 60 Yaş ve Üzeri Hodgkin Lenfomalı Hastalar. Geriatrics, Turkish Journal of Geriatrics 2003; 6(1):6-9. 101.Karaoğlu A, Yalçın Ş, Tekuzman G, Kars A, Çelik İ, Güler N, Özışık Y, Türker A, Barışta İ, Güllü İ.Weekly Irinotecan in Patients with Metastatic Colorectal Cancer Failing 5-Fluorouracil-Based Chemotherapy: Efficacy and Prognostic Factors. Tumori 2003; 89(2):141-145. 102.Barışta İ. Erişkinlerde Lenfoma Tedavisi. Hacettepe Tıp Dergisi 2003; 34(4): 229-235. 103.Yalçın Ş, Öksüzoğlu B, Tekuzman G, Engin H, Çelik İ, Türker A, Barışta İ, Güllü İ, Güler N, Altundağ K, Özışık Y, Kars A. Biweekly Irinotecan Plus Bolus 5- Fluorouracil and Folinic Acid in Patients with Advanced Stage Colorectal Cancer. Japanese Journal of Clinical Oncology 2003; 33(11):580-583. 104.Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease. American Journal ofClinical Oncology2004; 27(1):73-80. 105.Oyan B, Aksoy S, Yavas Ö, Kars A, Türker A, Barışta İ. Thymic Malignancy in a Breast Cancer Patient -- Is There an Association with Anti-estrogenic Effects of Tamoxifen? Acta Oncologica 2004; 43(1):115-116. 106.Abalı H, Barışta İ.Comments on Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone: Comparison of Two Strategies to Treat Diffuse Large B-Cell Lymphoma. Annals of Oncology 2004; 15: 841-842. 107.Koca E, Sokmensuer C, Yildiz BO, Engin H, BozkurtMF, Aras T, Barista I, Gurlek A. A Patient Presenting with Spinal Cord Compression Who Had Distinct Follicular Cell Type Thyroid Carcinomas. Journal of Endocrinologic Investigation2004; 27:562-564.

108.Gunay EC, Salanci, BV, Barista I, Caner B. Lung Hilar Ga-67 Uptake in PatientswithLymphoma Following Chemotherapy. Annals of Nuclear Medicine2004;18(5):391-397.

109.Yıldız F, Zengin N, Engin H, Güllü İ, Barışta İ, Çağlar M, Özyar E, Cengiz M, Gürkaynak M, Zorlu F, Caner B, Atahan İL, Tekuzman G. Prospective Study ofCombined Modality Treatment or Radiotherapy Alone in the Management ofEarly-Stage Adult Hodgkin’s Disease.International Journal of RadiationOncology, Biology, Physics 2004; 60(3):839-846.

110.Kılıçkap S, Barışta İ, Akgül E, Aytemir K, Aksöyek S, Aksoy S, Çelik İ, Kes S, Tekuzman G. cTnT Can Be a Useful Marker For Early Detection of Anthracycline Cardiotoxicity. Annals of Oncology; 2005: 16(5):788-804. 111.Kılıçkap S, Akgül E, Aksoy S, Aytemir K, Barışta İ. Doxorubicin-Induced Second Degree and Complete Atrioventricular Block. Europace 2005; 7(3):227-230. 112.Abali H, Oyan B, Koc Y, Kars A, Barista I, Uner A, Turker A, Demirkazik F, Tekin F, Tekuzman G, Kansu E. IIVP Salvage Regimen Induces High Response Rates in Patients with Relapsed Lymphoma Before Autologous Stem Cell Transplantation. American Journal of Clinical Oncology 2005;28(3):264-269. 113.Kilickap S, Barista I, Aytemir K. Reply to "Troponins in Prediction of Cardiotoxic Effects", by D. Cardinale et al. Annals of Oncology 2006;17(1):173-174. 114.Koca E, Duman A, Cetiner D, Buyukasik Y, Haznedaroglu I, Uner A, Demirhan B, Kerimoglu U, Barista I, Calguneri M, Ozcebe O. Succesful Treatment of Myelodisplastic Syndrome-Induced Pyoderma Gangrenosum. Netherlands Journal of Medicine 2006;64(11):422-424. 115.Dizdar O, Barista I, Kalyoncu U, Karadag O, Hascelik G, Cila A, Pinar A, Celik I, Kars A, Tekuzman G. Biochemical Markers of Bone Turnover in Diagnosis of Myeloma Bone Disease. American Journal of Hematology 2007;82(3):185-191. 116.Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S, Tekuzman G. Early and Late Arrhythmogenic Effects of Doxorubicin. Southern Medical Journal 2007;100(3): 262-265. 117.Barista I, Varan A, Ozyar E. Bimodal Age Distribution in Hodgkin’s Disease and Nasopharyngeal Carcinoma. Medical Hypotheses 2007;68(6):1421. 118.Dizdar O, Kalyoncu U, Karadag O, Akdogan A, Kiraz S, Ertenli I, Barista I, Calguneri M. Macrophage Inflammatory Protein-1alpha: A Link Between Innate Immunity and Familial Mediterranean Fever? Cytokine 2007;37(1):92-95. 119.Aksoy S, Harputluoglu H, Kilickap S, Sener Dede D, Dizdar O, Altundag K, Barista I. Rituximab-Related Viral Infections in Lymphoma Patients. Leukemia and Lymphoma 2007;48(7):1307-1312. 120. Dizdar O,Tapan U,Aksoy S, Harputluoglu H, Kilickap S, Barista I. Liver DysfunctionAfter Chemotherapy in Lymphoma Patients Infected with Hepatitis C. European Journal of Haematology 2008; 80(5):381-385 (Epub 2008 Jan 23). 121.Kilickap S, Yavuz B, Aksoy S, Sahiner L, Dincer M, Harputluoglu H, Erman M, Aytemir K, Tokgozoglu L, Barista I. Addition of Rituximab to CHOP Does Not Increase the Risk of Cardiotoxicity in patients with Non-Hodgkin’s Lymphoma. Medical Oncology 2008; 25:437-442 (Epub 2008 April 15). 122.Harputluoglu H, Dizdar O, Aksoy S, Kilickap S, Dede DS, Ozisik Y, Guler N, Barista I, Gullu I, Hayran M, Selek U, Cengiz M, Zorlu F, Tekuzman G, Altundag K. Characteristics of Breast Cancer Patients with Central Nervous System Metastases: A Single-Center Experience. Journal of the National Medical Association 2008; 100(5):521-526. 123.Barışta İ. Hızlı Seyirli (Agresif) Lenfomalar. Türkiye Klinikleri Tıbbi Onkoloji Özel Dergisi, Lenfoma Özel Sayısı 2009; 2(2):40-49. 124.Yildirim F, Karaduman A, Hurmuz P, Ozyar E, Barista I, Saglam A. Symmetrical Primary Cutaneous Marginal Zone Lymphoma Associated with Rheumatoid Arthritis. Journal of Cutaneous Pathology 2010;37(5):600-604 (Epub 2009 Aug 5). 125.Shorbagi A, Önal İK, Önal ED, Kılıçkap S, Barışta İ, Kansu T, Bayraktar Y. Fitting the Pieces of the POEMS Syndrome Jigsaw Puzzle - Guillain-Barré Syndrome in a Patient with Refractory Ascites: Case Report. Türkiye Klinikleri Tıp Bilimleri Dergisi (Turkish Journal of Medical Sciences) 2010;30(1):352-355. 126.Bazarbachi A, Azim HA, Alizadeh H, Aljurf M, Barista I, Chaudhri NA, Fahed Z, Fahmy OA, Ghavamzadeh A, Khalaf MH, Khatib S, Kutoubi A, Paydas S, Elayoubi HR, Zaatari G, Zawam HM, Zelenetz AD. Modification and Implementation of NCCN GuidelinesTM on Lymphomas in the Middle East and North Africa Region. Journal of the National Comprehensive Cancer Network 2010;8(Suppl 3):S29-S35. 127.Uner A, Akyurek N, Saglam A, Abdullazade S, Uzum N, Onder S, Barista I, Benekli M. The Presence of Epstein-Barr Virus (EBV) in Diffuse Large B-Cell Lymphomas (DLBCLs) in Turkey: Special Emphasis on “EBV-Positive DLBCL of the Elderly”. APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica2011;119(4-5):309-316 (Epub 2011 Mar 22). 128.Atay S, Barista I, Gundogdu F, Akgedik K, Arpaci A. Rapid-Infusion Rituximab in Lymphoma Treatment: 2-Year Experience in a Single Institution. Journal of Oncology Practice 2012;8(3):141-143 (Epub 24 Jan 2012). 129.Akyurek N, Uner A, Benekli M, Barista I. Prognostic Significance of Myc, Bcl2, and Bcl6 Rearrangements in Patients with Diffuse Large B-Cell Lymphoma Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone plus Rituximab. Cancer 2012;118(17):4173-4183 (Epub 27 Dec 2011). 130.Kilickap S, Barista I, Ulger S, Celik I, Selek U, Gullu I, Yildiz F, Kars A, Ozisik Y, Tekuzman G. Long-Term Complications in Hodgkin’s Lymphoma Survivors. Tumori 2012;98(5):601-606.

Hodgkin hastalığı ve Non-Hodgkin lenfoma tedavileri ile ilgilenmektedir.

Lise	TED Ankara Koleji 1978
Lisans	Hacettepe Tıp 1984
Yüksek Öğrenim	Doktora / Uzmanlık / İç Hastalıkları 1990 Tıbbi Onkoloji 1993
Yurtdışı Deneyim / Eğitim	2000-2001’de oniki ay süreyle ABD’de Houston, Texas’taki M. D. Anderson Kanser Merkezi’nde lenfoma tedavisi konusunda çalıştı.
Yabancı Dil	İngilizce

: (312) 305 29 45

: ibarista@hacettepe.edu.tr